Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/011752VONOPRAZAN SALT, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO 20.01.2022
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Appl.No PCT/CN2020/106149 Applicant HINYE PHARMACEUTICAL CO., LTD Inventor LIU, Junhua
Disclosed are a Vonoprazan salt, a preparation method therefor, and use thereof. The Vonoprazan salt of the present invention is a salt formed by Vonoprazan and a complex of an organic acid and bismuth. The present invention also covers a preparation method for the Vonoprazan salt and an application of the Vonoprazan salt in preparation of drugs for treating gastric acid diseases. Compared with existing Vonoprazan salts, the salt formed by Vonoprazan and the complex of the organic acid and bismuth of the present invention has a number of satisfactory advantages, such as good solubility and stability, increased bioavailability, and synergistically increased efficacy.
2.WO/2022/011992IMMUNE AGONIST COMPLEX FOR TREATING ALZHEIMER'S DISEASE
WO 20.01.2022
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No PCT/CN2020/141673 Applicant HANGZHOU XINGAO BIOTECHNOLOGY CO., LTD Inventor TAN, Xiangshi
Provided is an immune agonist complex for preventing or treating Alzheimer's disease or other neurodegenerative diseases, said immune agonist complex being composed of a brain metal ion homeostasis regulatory protein and transmembrane peptide fusion recombinant protein coupled liposome, and an innate immune agonist.
3.WO/2022/012172ORAL SUSTAINED-RELEASE COMPOSITION FOR INSOLUBLE DRUG, AND PREPARATION METHOD THEREOF
WO 20.01.2022
Int.Class A61K 9/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
Appl.No PCT/CN2021/095791 Applicant DIQI PHARMACEUTICLAS CO., LTD. Inventor LIU, Feng
An oral sustained-release composition for an insoluble drug, comprising a sustained- and controlled-release particle and a gel matrix, wherein the sustained- and controlled-release particle comprises an insoluble drug, an enteric-coated material, and a strong liquid absorption carrier, and the gel matrix comprises a hydrophilic gel matrix material; the sustained- and controlled-release particle is obtained by preparing a suspension from the insoluble drug and the enteric-coated material, and then spraying the suspension onto the strong liquid absorption carrier. The sustained-release particle is wrapped by the gel matrix to form a multi-sustained- and controlled-release system, thereby extending release time.
4.WO/2022/012622DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
WO 20.01.2022
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Appl.No PCT/CN2021/106482 Applicant BEIGENE, LTD. Inventor LEI, Bailin
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
5.WO/2022/013312PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS
WO 20.01.2022
Int.Class C07D 498/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/EP2021/069657 Applicant CHIESI FARMACEUTICI S.P.A. Inventor PALA, Daniele
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
6.WO/2022/013642PHOSPHATE-CONTAINING COPOLYMERS FOR VIRULENCE SUPPRESSION
WO 20.01.2022
Int.Class C08G 65/335
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
65Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
02from cyclic ethers by opening of the heterocyclic ring
32Polymers modified by chemical after-treatment
329with organic compounds
335containing phosphorus
Appl.No PCT/IB2021/055220 Applicant 3M INNOVATIVE PROPERTIES COMPANY Inventor LASKOWSKI, Carl A.
Phosphate-containing copolymers, medical compositions containing the phosphate-containing copolymers, and methods of suppressing microbial virulence are provided. By suppressing virulence, administration and/or application of the medical compositions can be used to prevent, mitigate, or treat a microbial infection. The phosphate-containing copolymers are prepared by phosphorylating either a random copolymer or a random copolymeric block that contains monomeric units of propylene oxide and glycidol.
7.WO/2022/014707TRPV4 INHIBITOR AS THERAPEUTIC DRUG FOR EYE DISEASE
WO 20.01.2022
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/JP2021/026829 Applicant RAQUALIA PHARMA INC. Inventor OHARA Kentaro
The present invention relates to the use of a compound having TRPV4 inhibitory activity, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing these, in the manufacture of a pharmaceutical product for the prevention or treatment of retinal disease that accompanies vascular disorders or cellular disorders. Further, the invention relates to a method of preventing or treating the aforementioned diseases, involving administering said compound or a pharmaceutical composition containing the same to a human or animal. Said compound, pharmaceutically acceptable salt thereof, or pharmaceutical composition containing these may be used in combination with one or more second active drugs. The invention relates to a kit and a pharmaceutical composition, used for the prevention or treatment of the aforementioned diseases and containing a compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof. The invention further relates to a marker for diagnosing diseases usefully treated by said compound, and a method for screening drugs that prevent or treat the aforementioned diseases.
8.WO/2022/015982COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
WO 20.01.2022
Int.Class A61K 31/4178
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4178not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
Appl.No PCT/US2021/041827 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor SCHALETZKY, Julia
The present disclosure provides methods of treating an RNA virus infection. The methods comprise administering combined effective amounts of an RNA-dependent RNA polymerase inhibitor, such as remdesivir, and a second therapeutic agent for treating infection with an RNA virus.
9.WO/2022/015997SMALL MOLECULE INHIBITORS OF TDP-43 ACTIVITY AND USES THEREOF
WO 20.01.2022
Int.Class A61K 31/553
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
553having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
Appl.No PCT/US2021/041852 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA Inventor KHANNA, May
This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of TDP-43 activity. The invention further relates to methods of treating and/or ameliorating symptoms related to conditions associated with TDP-43 activity (e.g., neurodevelopmental disorders), comprising administering to a subject (e.g., a human patient) a composition comprising one or more pharmaceutical agents which function as inhibitors of TDP-43 activity.
10.WO/2022/012456NOVEL HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
WO 20.01.2022
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/CN2021/105686 Applicant CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. Inventor FANG, Haiquan
Provided are heterocyclic compounds of formula (I) as bromodomain and extraterminal (BET) inhibitors, pharmaceutical compositions comprising the compounds, their synthesis and their use for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.